Metastat Inc · OTC:MTST
Metastat — Investor Presentation (January 2014)
33 slides from Metastat's investor presentation, Jan 15, 2014
Slide 1: MetaStat, Inc. Corporate Presentation
[STRICTLY PRIVATE AND CONFIDENTIAL MetaStat, Inc. Corporate Presentation January 2014 @MetaStat
Slide 2: Market Capitalization (as of 1/8/14)
STRCTLY PRIVATE AND CONFDENTIAL Market Capitalization (as of 1/8/14) Ticker OTCBB: MTST Price per share $1.56 Market cap $33.6 million Common shares outstanding. 21.5 million Full diluted shares outstanding 27.2 million * * Does not include conversion shares from he $1,987,000 principslamountof conv
Slide 3: Forward-Looking Statements
STRCTLY PRIVATE AND CONFDENTIAL Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intend
Slide 4: MetaStat Key Highlights
[STRCTLY PRIVATE AND CONFDENTIAL MetaStat Key Highlights + Systemic metastasis is responsible for 90% of all solid tumor cancer deaths The problem * However, many solid tumors are biologically incapable of metastasizing + Understanding the underlying biology of systemic metastasis inal epithelial-ba
Slide 5: Overview
STRCTLY PRIVATE AND CONFDENTIAL Section 1 OVERVIEW @MetaStat
Slide 6: Overview: The Metastatic Cancer Problem
STRCTLY PRIVATE AND CONFDENTIAL Overview: The Metastatic Cancer Problem Metastasis is responsible for 90% solid tumor cancer related deaths Only a fraction of solid tumors are biologically capable of metastatic spread = 30.35% of breast cancers = 15% of prostate cancers Majority of these patients ar
Slide 7: Overview: The MetaStat Solution
[STRCTLY PRIVATE AND CONFDENTIAL Overview: The MetatStat Solution © Minimize treatment for patients with favorable tumors MetaStat’s products have the potential to: * Maximally treat patients with aggressive tumors * Facilitate personalized and targeted cancer therapy * Benefit both patients and the
Slide 8: Experienced team with deep understanding of oncology
[STRCTLY PRIVATE AND CONFDENTIAL Experienced team with deep understanding of the clinical, scientific, and business aspects of oncology Management Team and Board of Directors Name Title Experience Oscar Chief Executive __* Diplomat, American Board of Surgery Bronsther, Officer and * Chairman, Sectio
Slide 9: Platform technology R&D by scientific and clinical team
[STRCTLY PRIVATE AND CONFDENTIAL Over 15 years of platform technology R&D by Scientific and Clinical team at leading academic research centers [institutional Afitation Albert Einstein lege of Medicine ‘The Judith andurtonP. Resnick Chair in Translational Research 1+ Profesor and co-chsiraf anatomy a
Slide 10: Technology
STRCTLY PRIVATE AND CONFDENTIAL Section 2 TECHNOLOGY @MetaStat
Slide 11: The Mena Story
STRCTLY PRIVATE AND CONFDENTIAL The Mena Story * Mena is an embryonic protein which in utero participates in the maturation of the central and peripheral nervous system * Post partum, expression of Mena is completely suppressed — i.e. healthy human beings have no measurable amount of Mena * Our fund
Slide 12: The Mena Story
STRCTLY PRIVATE AND CONFDENTIAL The Mena Story * We have been able to exploit this novel understanding to bring two distinctive Mena-based, products to the market: = MetaSite Breast — an immunohistochemistry test that exploits our discovery that a 3 cell micro-anatomical unit self-assembles in women
Slide 13: Metastatic Cancer Cell Opening the Blood Vessel Wall
STRICTLY PRIVATE AND CONFDENTIAL Metastatic Cancer Cell Opening the Blood Vessel Wall Metastatic cell opening the blood vessel wall @MetaStat
Slide 14: The MetaSite and the Moment of Metastasis
STRICTLY PRIVATE AND CONFDENTIAL The MetaSite and the Moment of Metastasis © The micro-anatomical site of intravasation * “Window” into the bloodstream that metastatic cells squeeze through to begin their deadly spread @MetaStat
Slide 15: The MetaSite: Window Where Systemic Metastasis Takes Place
STRCTLY PRIVATE AND CONFDENTIAL The MetaSite: Window Where Systemic Metastasis Takes Place Three cells in apposition + Red Metastatic Cell (Mena +) — Pan-Mena MAB + Blue Endothelial Cell — CD31 MAB * Brown Macrophage ~ CD68 MAB Triple Immuno- histochemical Stain @MetaStat
Slide 16: MetaStat has Strong IP Positions
[STRCTLY PRIVATE AND CONFDENTIAL MetaStat has Strong IP Positions us us Europe Canada us Europe us us us Canada Europe Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors (Di & Drug Screening-MenaCale) Metastasis specific splice variants of Me
Slide 17: Encouraging Clinical Validation Studies
[STRCTLY PRIVATE AND CONFDENTIAL Encouraging Clinical Validation Studies 3 trials consisting of a total of 585 patients MetaSite Breast 481 of those in a validation study pending publication Highly prognostic for ER+, HER2- (~60% of all breast cancer patients) 2 trials consisting of a total of 1203
Slide 18: Supporting publications in leading peer-reviewed journals
STRICTLY PRIVATE ANO CONFDENTIAL Supporting publications in leading peer-reviewed scientific journals Clinical Developmental nature Cancer Research | ‘MetaStat’s research team has published 24 articles in 10° leading US and international science journals @MetaStat
Slide 19: Product Portfolio
STRCTLY PRIVATE AND CONFDENTIAL Section 3 PRODUCT PORTFOLIO @MetaStat
Slide 20: Product Portfolio
[STRCTLY PRIVATE AND CONFDENTIAL Product Portfolio MetaStat is developing complimentary diagnostic and therapeutic products PRODUC PRODUCT TYPE | CANCERTYPE | LAUNCH YEAR DESCRIPTION Diagnostics Breast, FY 2015 A diagnostic that predicts the likelihood of cancer metastasizing based on the density of
Slide 21: Product Roadmap - Commercialization in 2015
STRCTLY PRIVATE AND CONFDENTIAL Product Roadmap - Commercialization in 2015 2014 2016 2017 2018 2019 MetaStat Portfolio Prostate Development Timeframe * Utilize R&D synergies by employing data from diagnostics program to accelerate therapeutic development Strategy offers a unique and highly attracti
Slide 22: Market Opportunity
STRCTLY PRIVATE AND CONFDENTIAL Section 4 MARKET OPPORTUNITY @MetaStat
Slide 23: Market Opportunity: Breast Cancer Diagnostics
STRCTLY PRIVATE AND CONFDENTIAL Market Opportunity: Breast Cancer Diagnostics * ASCO & NCCN recommend breast cancer diagnostic testing * The current genomic tests on the market (est. to be ~$250-$275MM) have limited applicability = Inherent problems with tests based on bio-statistically derived algo
Slide 24: $1.7B annual market opportunity for MetaStat's diagnostic products
STRCTLY PRIVATE AND CONFDENTIAL A$1.7B annual market opportunity for MetaStat’s diagnostic products Number of new _| Addressable Product cases per year Marke! MetaSite Breast 232,000 60 MenaCalc - Breast 232,000 40 MenaCalc - Lung 226,160 40 MenaCalc - Prostate 241,740 100 MenaCale - CRC 143,460 100
Slide 25: MetaSite and MenaCalc will fit into existing clinical workflow
STRCTLY PRIVATE AND CONFDENTIAL MetaSite and MenaCalc will easily fit into existing clinical workflow ‘orrent Workfiow Presents Suspicious Lesion Bopsied — ae [— >| = |, | ee Metastatic Workup Malignant or Benign mataliiel @MetaStat
Slide 26: Regulatory and Reimbursement
[STRCTLY PRIVATE AND CONFDENTIAL Regulatory and Reimbursement MetaStat’s diagnostic tests only require CLIA certification (FDA approval I pop etocy) not required at this time) allowing for market entry in 2015 MetaSite Breast™ and MenaCalc™ diagnostic tests are eligible for 3rd party reimbursement u
Slide 27: MetaStat's Therapeutic Program
STRCTLY PRIVATE AND CONFDENTIAL Section 5 METASTAT’S THERAPEUTIC PROGRAM @MetaStat
Slide 28: Therapeutic MenaBloc Platform
[STRCTLY PRIVATE AND CONFDENTIAL Therapeutic MenaBloc Platform Challenges * Identify new targets in oncology ‘* MenaBloc will build upon Mena biology and alternative splicing as a driver of disease progression to exploit novel targets that provide precision medicines * Lack of molecular targeted the
Slide 29: Therapeutics Program
STRCTLY PRIVATE AND CONFDENTIAL Therapeutics Program Metastat will build a platform for identification and validation of alternatively spliced targets for oncology * Alternative splicing yields unique proteins with altered function © Alternative splicing events are observed in cancer and other disea
Slide 30: Companion Diagnostics
STRCTLY PRIVATE AND CONFDENTIAL Companion Diagnostics The use of companion diagnostics is critical to success in matching new drug discoveries to the appropriate patient population * American Society of Clinical Oncology (ASCO) guidelines urge cancer research practice to include identification of ap
Slide 31: Financial Projections
STRCTLY PRIVATE AND CONFDENTIAL Section 6 FINANCIAL PROJECTIONS @MetaStat
Slide 32: Financial Projections
[STRCTLY PRIVATE AND CONFDENTIAL Financial Projections Projected MetaSite™ and MenaCalc™ Breast [il Tests sold (Thousands) [fl Revenue (millions) $80.0 2017 2018 ” @MetaStat
Slide 33: MetaStat can change the current cancer treatment paradigm
[STRCTLY PRIVATE AND CONFDENTIAL MetaStat can change the current cancer treatment paradigm with its diagnostic and therapeutic products Value Proposition Diagnostic Tools New Cancer Diagnostic Paradigm MetaSite Breast™ MenaCalet =o New Cancer Treatment Paradigm Therapeutic so @MetaStat